

13 December 2019

Market Announcements
Australian Securities Exchange Ltd

Vita Life Sciences Limited

ACN 003 190 421 ABN 35 003 190 421

Corporate Office

1/102 Bath Road, Kirrawee NSW 2232 P.O. Box 3143

Kirrawee NSW 2232

T/Free: 1800 852 222 T: 02 9545 2633 F: 02 9545 1311 vitalifesciences.com

SALES & PROFIT GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the financial year ending 31 December 2019:

Sales: \$41.0m-\$41.5m (2018: \$41.1m) **Underlying EBIT**: \$3.2-\$3.7m (2018: \$6.2m) **Statutory EBIT**: \$3.5m-4.0m (2018: \$4.4m)

Challenging retail conditions have influenced full year growth expectations across the Group. Whilst sales from traditional distribution channels remains soft, the expansion gains into new Pharmacy and Export channels have been positive. Higher advertising and promotional activities, combined with increased operating overheads required to support the expansion strategy, impacted the Underlying and Statutory EBIT result.

Andrew O'Keefe Managing Director

Achua

Email: enquiries@vitalifesciences.com.au







